Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s growth drivers, including the FreeStyle Libre, electrophysiology products, leadless pacemakers, and cardiovascular devices, as well as its ability to develop and launch new products, could lead to continued growth in sales and earnings, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $158 from $149 at Barclays
- Abbott price target raised to $135 from $130 at Stifel
- Abbott price target raised to $138 from $135 at Bernstein
- Abbott price target raised to $148 from $146 at UBS, shares remain undervalued
- Abbott Laboratories Reports Strong 2024 Financial Results